Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Qianweitai (Silodosin Capsule) Compared to Tamsulosin in the Treatment of Benign Prostaic Hyperplasia (BPH) -A Multicenter, Prospecive, Randomized, Investigator-Blind, Positive-Controlled Study

NCT07134907 is registered in ClinicalTrials.gov with Shanghai Huilun Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07134907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07134907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Qianweitai (Silodosin Capsule) Compared to Tamsulosin in the Treatment of Benign Prostaic Hyperplasia (BPH) -A Multicenter, Prospecive, Randomized, Investigator-Blind, Positive-Controlled Study
Lead sponsor
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
July 18, 2022
Completion date
July 9, 2024
Enrollment
110 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bph (benign prostatic hyperplasia)